

# Trikafta Patent, Sales & Clinical Trials Insight 2028

<https://marketpublishers.com/r/T2279A22FBA1EN.html>

Date: October 2021

Pages: 72

Price: US\$ 800.00 (Single User License)

ID: T2279A22FBA1EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Trikafta Patent, Sales & Clinical Trials Insight 2028 Report Analysis & Data Highlights:

Trikafta Patent Insight

Trikafta Dosage & Price

Trikafta Sales Forecast 2028: > USD 5 Billion

Trikafta Chemistry & Pharmacokinetic Properties

Trikafta Ongoing Clinical Trials: > 15 Clinical Studies

Role in Cystic Fibrosis

Trikafta Reimbursement Scenario

The successful mapping of human genome and advances in molecular technology has led to evolution of targeted therapies. The identification of cystic fibrosis transmembrane conductor regulator (CFTR) gene and its potential role in the progression of cystic fibrosis has surged the research and development of targeted drugs towards CFTR genes. Researchers have developed CFTR modulator agents which are small molecules which modulate the function of abnormal CFTR protein. To date, four CFTR modulators have been approved for the treatment of cystic fibrosis.

Trikafta is the first triple combinational therapy involving elexacaftor, tezacaftor, and

ivacaftor. The drug is indicated for the management of cystic fibrosis in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The novel drug Trikafta was designed to increase the quantity and function of the F508del-CFTR protein at the cell surface. The drug has gained approval in US and Europe. It is expected that the drug will also be approved in China and Japan during the forecast period, which will further propel the market.

The approval of drug Trikafta was supported by the positive results of two global Phase 3 studies in people ages 12 years and older with cystic fibrosis including a 24-week Phase 3 study in 403 people with one F508del mutation and one minimal function mutation (F/MF) and a 4-week Phase 3 study in 107 people with two F508del mutations (F/F). The results from the trial indicated that clinically meaningful improvements were seen in patients and the drug has demonstrated safety and tolerability in cystic fibrosis patients.

The entrance of the drug Trikafta has greatly revolutionized the overall cystic fibrosis treatment as it combines the properties of all three previously approved CFTR modulators. Owing to its high specificity towards of cystic fibrosis transmembrane conductor regulator (CFTR) gene and ability to overcome the resistance limitations of already approved drugs, the report analyzes that the coming years will witness high growth rates in the global sales of Trikafta.

Important advances in the clinical outcomes have been shown since the introduction of Trikafta. Unfortunately, the therapy is currently associated with substantial cost and as results is not available for all eligible patients. However, considerable initiatives by government and public sectors have led to the development of favorable reimbursement policies which aim to enhance their uptake in market. For instance, Vertex GPS program was developed which provide financial support services, reimbursement support, and ongoing product-related materials for eligible enrolled patients who have been prescribed Trikafta.

The report offers compressive analysis on the growth of Trikafta market during the forecast period 2021-2028 by taking into considerations several parameters including previous sales, competition from other drugs, increasing prevalence of cystic fibrosis, and unmet need of targeted drugs. The overall CFTR modulator market is highly competitive and consists of several pharmaceutical companies including Vertex Pharmaceuticals, Eloxx, Recode Therapeutics and Corbus Pharma which are investing huge amount in the development of novel CFTR modulators in the management of

disease.

As per report findings, the global Trikafta market is estimated to surpass USD 5 Billion by 2028. The high growth rate during the forecast period can be justified by the high adoption rates in US and Europe. In addition, several ongoing clinical trials are also evaluating the role of drug in other mutations in different age groups, which are expected to gain approval in coming years.

## Contents

### **1. ELEXACAFTOR/IVACAFTOR/TEZACAFTOR (TRIKAFTA/KAFTRIO)**

- 1.1 Overview
- 1.2 Patent & Assignees

### **2. TRIKAFTA COMMERCIAL INFORMATION**

- 2.1 Pricing & Dosage Analysis
- 2.2 Sales Analysis

### **3. ROLE IN CYSTIC FIBROSIS**

- 24. Trikafta Mechanism of Action

### **5. TRIKAFTA: CHEMISTRY & PHARMACOKINETIC PROPERTIES**

### **6. TRIKAFTA SALES FORECAST 2028**

### **7. TRIKAFTA SUPPLEMENTARY INFORMATION**

- 7.1 Drug Interactions
  - 7.1.1 Potential for other drugs to affect elexacaftor/tezacaftor/ivacaftor
  - 7.1.2 Potential for elexacaftor/tezacaftor/ivacaftor to affect other drugs
- 7.2 Adverse Events
- 7.3 Use in Specific Population

### **8. TRIKAFTA REIMBURSEMENT**

### **9. TRIKAFTA CLINICAL TRIAL INSIGHTS**

- 9.1 By Phase
- 9.2 By Region
- 9.3 By Status

### **10. GLOBAL MARKET ANALYSIS**

- 10.1 Current Market Scenario
- 10.2 Future Market Opportunity

## **11. ONGOING CLINICAL TRIALS**

## **12. COMPETITIVE LANDSCAPE**

- 12.1 Abbvie
- 12.2 Eloxx Pharmaceuticals
- 12.3 GlaxoSmithKline
- 12.4 Mylan
- 12.5 Recode Therapeutics
- 12.6 Roche
- 12.7 Southern Research Institute
- 12.8 Spirovant Sciences
- 12.9 Translate Bio
- 12.10 Vertex Pharmaceuticals

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: US - Trikafta Orphan Drug Designation & FDA Approval Year
- Figure 1-2: Europe - Trikafta Orphan Drug Designation & EMA Approval Year
- Figure 1-3: US - Trikafta FDA Approval History by Mutation
- Figure 1-4: US - Trikafta FDA Approval History in F508del Mutation by Age
- Figure 1-5: Trikafta/Kaftrio - Initial Approval Year by Region
- Figure 1-6: Europe - Kaftrio Approval & Patent Expiration Year
- Figure 1-7: US - Trikafta Approval & Patent Expiration Year
- Figure 1-8: US - Trikafta Patent Approval & Expiration Year
- Figure 2-1: US - Cost of Supply of 84 Oral Tablet & Per Unit Cost of Trikafta Oral Tablet (US\$), October'2021
- Figure 2-2: Europe - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Kaftrio Oral Tablet (Euro/US\$), October'2021
- Figure 2-3: UK - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Kaftrio Oral Tablet (Euro/US\$), October'2021
- Figure 2-4: Trikafta/Kaftrio - Recommended Initial & Reduced Dose (mg/day)
- Figure 2-5: Trikafta – Average Cost of Daily, Monthly & Annual Treatment of Cystic Fibrosis (US\$), October'2021
- Figure 2-6: Global - Trikafta/Kaftrio Annual Sales (US\$ Million), 2019 & 2020
- Figure 2-7: Global - Trikafta/Kaftrio Quarterly Sales (US\$ Million), 2020
- Figure 2-8: Global - Trikafta/Kaftrio Quarterly Sales (US\$ Million), Q1 & Q2'2021
- Figure 3-1: Frequency of CFTR Mutation by Class
- Figure 4-1: CFTR Modulators – Specific Target for Different Approaches
- Figure 4-2: Trikafta – Mechanism of Action at Molecular Level
- Figure 5-1: Elexacaftor – Chemical Structure
- Figure 5-2: Chemical Structure of Ivacaftor & Tezacaftor
- Figure 6-1: Trikafta – Expected Sales Analysis (US\$ Million), 2021 - 2028
- Figure 9-1: Trikafta – Number of Clinical Trials by Phase, October'2021
- Figure 9-2: Trikafta – Number of Clinical Trials by Phase (%), October'2021
- Figure 9-3: Trikafta – Number of Clinical Trials by Region, October'2021
- Figure 9-4: Trikafta – Number of Clinical Trials by Region (%), October'2021
- Figure 9-5: Trikafta – Number of Clinical Trials by Status, October'2021
- Figure 9-6: Trikafta – Number of Clinical Trials by Status (%), October'2021
- Figure 10-1: Global – CFTR Modulator Market by Product (US\$ Billion), 2020
- Figure 10-2: Global – CFTR Modulator Market by Product (%), 2020
- Figure 10-3: Global – CFTR Modulator Market by Product (US\$ Billion), H1'2021

Figure 10-4: Global – CFTR Modulator Market by Product (%), H1'2021

Figure 10-5: Global – Estimated Cystic Fibrosis Incidence, 2021-2028

Figure 10-6: Global – Trikafta Market Opportunity in Cystic Fibrosis by 5% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-7: Global – Trikafta Market Opportunity in Cystic Fibrosis by 10% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-8: Global – Trikafta Market Opportunity in Cystic Fibrosis by 15% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-9: Global – Trikafta Market Opportunity in Cystic Fibrosis by 20% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-10: Global – Trikafta Market Opportunity in Cystic Fibrosis by 25% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-11: Global – Trikafta Market Opportunity in Cystic Fibrosis by 30% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-12: Global – Trikafta Market Opportunity in Cystic Fibrosis by 35% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-13: Global – Trikafta Market Opportunity in Cystic Fibrosis by 40% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-14: Global – Trikafta Market Opportunity in Cystic Fibrosis by 45% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-15: Global – Trikafta Market Opportunity in Cystic Fibrosis by 50% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-16: US – Estimated Cystic Fibrosis Incidence, 2021-2028

Figure 10-17: US – Trikafta Market Opportunity in Cystic Fibrosis by 5% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-18: US – Trikafta Market Opportunity in Cystic Fibrosis by 10% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-19: US – Trikafta Market Opportunity in Cystic Fibrosis by 15% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-20: US – Trikafta Market Opportunity in Cystic Fibrosis by 20% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-21: US – Trikafta Market Opportunity in Cystic Fibrosis by 25% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-22: US – Trikafta Market Opportunity in Cystic Fibrosis by 30% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-23: US – Trikafta Market Opportunity in Cystic Fibrosis by 35% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-24: US – Trikafta Market Opportunity in Cystic Fibrosis by 40% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-25: US – Trikafta Market Opportunity in Cystic Fibrosis by 45% Adoption Rate (US\$ Million), 2021 - 2028

Figure 10-26: US – Trikafta Market Opportunity in Cystic Fibrosis by 50% Adoption Rate (US\$ Million), 2021 - 2028

Figure 11-1: Trikafta – Phase-III Evaluating Long Term Efficacy in CF with F508del Mutation Initiation & Completion Year

Figure 11-2: Trikafta – Phase-III Evaluating Long Term Efficacy in CF with F/MF Mutation Initiation & Completion Year

Figure 11-3: Trikafta – Phase-III Evaluating Effect on Cough & Physical Activity Initiation & Completion Year

Figure 11-4: Trikafta – Phase-III Evaluating Glucose Tolerance in CF Initiation & Completion Year



## I would like to order

Product name: Trikafta Patent, Sales & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/T2279A22FBA1EN.html>

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T2279A22FBA1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970